Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ReNeuron will begin clinical trial shortly; upbeat on potential deals

The cell technology group said the first of a group of 110 patients taking part in PICSE III will be enrolled soon
picture of an eye
Eye, eye: The company is in negotiations to out-license technology designed to treat retinal disease

ReNeuron Group PLC (LON:RENE) will tell investors at its annual meeting that a Phase IIb clinical trial of its potentially breakthrough CTX cell treatment for stroke will soon get underway in the US.

The first of a group of 110 patients taking part in PICSE III will be enrolled ‘shortly’.

WATCH: 'All systems go' with ReNeuron Group Plc looking to treat first PISCES III patient shortly

Top-line data from the randomised, placebo-controlled study is expected in early 2020, having been previously penciled in for the end of 2019.

In the update, the company said it expected to sign a definitive licensing agreement for its cell-based retinal technology later this year.

It has received a US$2.5mln exclusivity payment and will get the same again from an unnamed potential partner once the due diligence process is concluded.

Negotiations on other collaborations and out-licensing transactions continue.

“These potential deals, if successfully concluded, will provide strong third-party validation to our technologies and programmes as well as a source of significant non-dilutive funding to the company,” investors at the ReNeuron AGM will hear.

Specialist in cell science 

As mentioned above, ReNeuron is a cell therapy specialist. Its CTX line is being developed for stroke patients, while its hRPC stem cell candidate has been used to treat people with retinitis pigmentosa.

The study has now expanded to target people with less impaired vision and the first read-out from this early-stage trial is expected by the middle of next year.

The group's hRPC cells will also be deployed in the phase II study of sufferers of cone-rod dystrophy, which will run in parallel with a planned phase IIb in retinitis pigmentosa.

Turning to ReNeuron's exosome nanomedicine platform, the group's research team presented positive pre-clinical data on an ExoPr0 therapy, which has the potential to target multiple diseases. The plan is to lodge an initial clinical trial application next year for its use in cancer.

View full RENE profile View Profile

ReNeuron Group Plc Timeline

Related Articles

scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use